SCPX: NightHawk Biosciences EV/EBITDA Multiple

Symbol and logo of brand Scorpius Holdings (SCPX)

This chart of Scorpius Holdings, Inc. (SCPX) stock quotes demonstrates an EV/EBITDA of . Scorpius Holdings, Inc. operates as a CDMO provider, maintaining plant autonomy while remaining partially dependent on reagent suppliers. High barriers to entry are ensured by GMP certifications and the availability of sterile laboratories for government contracts. Yields are supported by rare cell cultivation capacities, although business scaling is temporarily reducing margins due to discounts provided to key customers.

SCPX Scorpius Holdings, Inc: Total Company Value to Operating Income Before Depreciation Ratio in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Scorpius Holdings, Inc.

- stock price and consensus target price:
Stock Quotes NightHawk Biosciences|SCPX - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Scorpius Holdings, Inc|SCPX - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Scorpius Holdings|SCPX - Book Valuation of Business|Market Cap to Net Assets Ratio nighthawkbio.com|SCPX - Aggregate Business Assets
- debt and liquidity data:
Debt to Equity Scorpius Holdings, Inc.|SCPX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Scorpius Holdings, Inc|SCPX - Company Total Debt Obligations|Debts to Book Capitalization Scorpius Holdings Inc.|SCPX - Company Long-Term Liabilities|Company Short-Term Debt Scorpius Holdings|Quick Liquidity nighthawkbio.com
- business earnings and investment ratios data:
SCPX - Final Profit|Expected Profit Scorpius Holdings, Inc.|SCPX - Market Cap to Net Income|Forward P/E Multiple Scorpius Holdings Inc.|SCPX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Scorpius Holdings|SCPX - Operating profit EBITDA|Earnings per share for the last twelve months Scorpius Holdings|SCPX - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months nighthawkbio.com|SCPX - Earnings per share increase in current year|Earnings growth forecast for next year Scorpius Holdings, Inc.
- sales volume and revenue indicators:
SCPX - Company Sales Revenue|Company Projected Revenue Scorpius Holdings Inc.|SCPX - Price to Sales|Price-to-Projected Revenue Ratio Scorpius Holdings, Inc.|SCPX - Sales Growth YoY (Last Twelve Months)
Comprehensive company analysis:nighthawkbio.com SCPX
Original product of Scorpius Holdings

Fundamental asset screening requires an accurate business valuation that accounts for debt obligations. The EV/EBITDA ratio trajectory reflects the relationship between total enterprise value and operating profit, making it possible to determine the degree of company undervaluation regardless of the tax regime or capital structure. For Scorpius Holdings, Inc. (SCPX), this indicator confirms investment attractiveness amid the brand's growing authority in the biopharmaceutical contract manufacturing segment.

Competitors of Scorpius Holdings, Inc. (SCPX)

EV/EBITDA Multiple IQV (IQVIA Holdings)|Total Company Value to Operating Income Before Depreciation Ratio Labcorp (LH)|Medpace Corp - EV/EBITDA Multiple|Company Value to EBITDA ICON Corp|CRL (Charles River) - Enterprise Value to EBITDA Ratio|EVO: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio FTRE|LFCR (lifecore.com) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OmniAb Inc. (OABI)|Total Company Value to Operating Income Before Depreciation Ratio Inotiv|EV/EBITDA Multiple CDMO (Avid Bioservices Inc.)|CTLT - Enterprise Value to EBITDA Ratio